|
Skin infections in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy |
|||||||||
| Time to event |
|||||||||
|
|
|||||||||
| Infection |
No. of events |
Median |
Range |
Druga (no.) |
Active treatmentb (no.) |
Rechallenge (no.) |
Permanent withdrawal of anti-TNF-αc (no.) |
Biopsy (no.) |
Cultured species |
|
|
|||||||||
| Fungal |
20 |
8.7 |
1.1–61.1 |
||||||
| Dermatomycosis |
9 |
A 3, I 4, E 2 |
7 |
0 |
1 |
Trichophyton verrucosum (1) T. rubrum (1) |
|||
| Onychomycosis |
3 |
A 3 |
3 |
0 |
0 |
||||
| Combination |
5 |
A 3, I 1, L 1 |
4 |
0 |
1 |
Trichophyton rubrum (3) T. mentagrofytes (1) |
|||
| Candidiasis |
3 |
I 3 |
2 |
0 |
0 |
Candida spp. (2) |
|||
| Bacterial |
11 |
9.5 |
1.4–52.5 |
||||||
| Folliculitis |
5 |
A 3, E 2 |
4 |
yes, negative |
1 |
2 |
Staphylococcus aureus (1) |
||
| Erysipelas |
3 |
E 2, I 1 |
3 |
yes, negative |
2 |
1 |
|||
| Bacterial superinfection of eczema |
2 |
A 1, I 1 |
1 |
yes, positive |
1 |
0 |
|||
| Furuncle |
1 |
I 1 |
0 |
0 |
0 |
||||
| Viral – herpes zoster |
2 |
17.3, 40.9d |
A 1, I 1 |
0 |
0 |
0 |
|||
|
aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bDuring active treatment with TNF-α-blocking therapy. cPermanent discontinuation of TNF-α-blocking therapy due to the event.d Individual values | |||||||||
Flendrie et al. Arthritis Research & Therapy 2005 7:R666 doi:10.1186/ar1724 |
|||||||||